Updated molecular testing guideline strongly recommends ROS1 testing for NSCLC

An 2018 update to the lung cancer molecular testing guideline says testing for ROS1 rearrangements is strongly recommended for all lung cancer patients regardless of clinical characteristics.

The article “Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors” was published online January 23, 2018, in the Journal of Molecular Diagnostics by a partnership of three organizations:

  • College of American Pathologists (CAP)
  • International Association for the Study of Lung Cancer (IASLC)
  • Association for Molecular Pathology (AMP)

REFERENCES:

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors (Journal of Molecular Diagnostics)

AMP article about the updated guideline

Published by

Gray Connections

I was diagnosed with non-small cell lung cancer in May 2011. The cancer became metastatic in October 2011. No, I never smoked anything (except a salmon). I've had no evidence of disease since January 2013 thanks to precision medicine, clinical trials, and other patients. ANYONE can get lung cancer. Using my engineering degrees (MIT SBME 1978, Caltech Aeronautics MS 1984 and ENGR 1986), I enjoyed a 20-year career in aerospace systems engineering as a technical translator of sorts: I researched a scientific or engineering subject and helped others understand how this new gizmo could benefit them. In the time I have left, I want to use my skills to help others who have lung cancer, and increase the visibility and knowledge of lung cancer among those who don't. I also study brain research, enjoy traveling, write science fiction, and geek out about all sorts of science stuff.